Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Go back to Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma| (NASDAQ: ERAS) | Delayed: 14.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.77 | 52 Week High | $ | |||
| Open | $14.77 | 52 Week Low | $ | |||
| Day High | $14.77 | P/E | N/A | |||
| Day Low | $14.77 | EPS | $ | |||
| Volume | 798 | |||||
